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CommentaryModifying the Glycome in Pigs for
Xenotransplantation
Peter J. Cowan, PhD1 and Robert Rieben, PhD2Inactivation of glycosyltransferase genes during humanevolution is a fundamental cause of differential glyco-
sylation in humans and pigs, resulting in the presence of
carbohydrate structures on pig cells that are recognized
by natural (preexisting) human antibodies. αGal, the first
of these epitopes to be identified, is synthesized by α1,3-
galactosyltransferase, encoded by theGGTA1 gene. The cru-
cial importance of αGal in solid organ xenotransplantation
was demonstrated by the finding that knockout of GGTA1
prevented hyperacute rejection in the pig-to-nonhuman pri-
mate (NHP) preclinical model. However, there is evidence
to suggest that knockout of additional glycosyltransferase
genes will further improve the “compatibility” of porcine xe-
nografts. One such gene is CMAH, which is responsible for
the synthesis of N-glycolylneuraminic acid (Neu5Gc).
The development of efficient genome editing techniques
(ZFNs, TALENs, and CRISPR/Cas9) has revolutionized the
genetic engineering of donor pigs, allowing precise and rapid
targeted mutagenesis in cultured primary cells, which can
then be cloned by somatic cell nuclear transfer. The Tector
group was the first to adopt this technology to knock out
multiple glycosyltransferase genes, namely, GGTA1 and
CMAH.1 When tested against 121 human serum samples,
peripheral blood mononuclear cells from double-knockout
(DKO) pigs generally bound less antibody than GGTA1
single-KO cells.2
In this issue of Transplantation, the group presents pre-
liminary evidence that the elimination of Neu5Gc may have
benefits in pig liver xenotransplantation beyond reducing
the binding of natural antibodies.3 In vivo and ex vivo
models have shown that pig livers rapidly sequester human
and NHP platelets, resulting in the development of life-
threatening thrombocytopenia in the pig-to-baboon model
(reviewed by Ekser et al4). Inhibition and knockout studies
indicate that the asialoglycoprotein receptor-1 (ASGR-1)
plays an important role in the binding of human and NHP
platelets to porcine endothelium,5,6 whereas deletion of αGal
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platelets and found that DKO livers sequestered significantly
fewer platelets than eitherGGTA1KOorWT livers, suggest-
ing for the first time the involvement of Neu5Gc in xenoge-
neic platelet uptake. The authors go so far as to propose
that the DKO modification is more effective than ASGR-1
KO, although some fine tuning of the model was needed
to demonstrate this quite subtle difference. Nevertheless,
the potential importance of this finding is that eliminating
Neu5Gc may kill two birds with one stone: reducing the tar-
gets for non-Gal antibodies, and solving a key problem in
liver xenotransplantation.
The study by Butler et al3 is a pure in vitro and ex vivo in-
vestigation and focuses on binding of human platelets to por-
cine liver endothelial cells in the absence of innate immune
mechanisms such as the complement and coagulation cas-
cades. It therefore remains to be seen whether the reduced
platelet binding to DKO livers can be confirmed, for exam-
ple, in perfusion experiments with whole human blood. In
addition, the study does not address the mechanism linking
Neu5Gc to the binding and phagocytosis of human platelets
by porcine liver endothelial cells. It will be very important
to understand what deleting Neu5Gc does to the endothelial
glycocalyx and its anticoagulant and anti-inflammatory func-
tion. Which sugars are expressed on the endothelium when
both αGal andNeu5Gc are missing? How does this influence
the binding of regulatory proteins and growth factors from
the plasma, which are known to be important for endothelial
function? Last but not least, could it be that the ASGR-1 ex-
pression or function is altered in the DKO pig livers?
A companion paper in the current issue8 looks at the ef-
fect of deleting a third porcine glycosyltransferase, β1,4 N-
acetylgalactosaminyl transferase 2, which is encoded by
B4GALNT2 and is thought to synthesize a xenoantigen sim-
ilar to the SDa blood group antigen in humans.9 The first im-
portant finding by Wang et al8 is that renal microvascular
endothelial cells (RMEC) from DKO pigs show less binding
of natural antibodies in pooled human serum than GGTA1
KO cells; this confirms the potential benefit of the CMAH
KO in a cell type that is arguably more relevant in xenograft
rejection than previously studied cells. They then immortal-
ized the RMEC and deleted B4GALNT2 using CRISPR/
Cas9 and demonstrated a small but significant further reduc-
tion in binding of human natural antibodies to the triple-KO
(TKO) cells. The fact that the binding of preformed, naturally
occurring human antibodies to the DKO and TKO RMEC is
reduced suggests that the genetically modified pig cells may
express some carbohydrate structures on their surface, which
are similar to the ones on human cells. Whether this is indeed
the case remains to be studied. It is also as yet unclear
whether the manipulation of the pig glycome as used here
will have other, completely unforeseen consequences aswww.transplantjournal.com 485
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the TKO pigs will be viable.
Together, these papers highlight the power of genome
editing and show, at least in principle, the scope and relative
ease of progressive “carbohydrate remodeling” to reduce the
antigenicity of pig xenografts.
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